ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors
· Medical Xpressby Lori Solomon
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
reputable news agency
proofread
The GIST Add to Preferred Sources
Sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant benefits for adults aged 80 years and older with chronic kidney disease (CKD), according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 21 to 25 in Denver.
Julian Doricic, M.D., from Medizinische Hochschule Hannover in Germany, and colleagues examined effects of SGLT2 inhibitor therapy in elderly adults with CKD. The analysis included 23,765 SGLT2 inhibitor users and nonusers (aged 80 years and older) who were propensity score-matched for comorbidities, laboratory parameters and frailty-associated factors, identified from the TriNetX database.
The researchers found that after two years of follow-up, there was a significant reduction in mortality among patients treated with SGLT2 inhibitors (adjusted hazard ratio [aHR], 0.734). A similar mortality benefit was seen across all predefined subgroups. SGLT2 inhibitor users also experienced benefits in terms of lower risk of both major adverse cardiovascular events (aHR, 0.884) and major adverse kidney events (aHR, 0.775).
"Very elderly individuals are historically underrepresented in or systematically excluded from large-scale randomized controlled trials due to multimorbidity and frailty. By leveraging real-world data, our research addresses a crucial blind spot in current medical literature," co-author Bernhard M.W. Schmidt, M.D., from Hannover Medical School in Germany, said in a statement. "These patients require a careful, individualized risk-benefit assessment and close clinical monitoring."
More information
Key medical concepts
Chronic Kidney DiseaseSodium-Glucose Transporter 2 Inhibitors [MoA]Mortality
Clinical categories
NephrologyHealthy aging Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors (2026, November 2) retrieved 2 November 2026 from https://medicalxpress.com/news/2026-11-asn-elderly-chronic-kidney-disease.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.